On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: World Wrestling Entertainment Inc. (NYSE:WWE), OvaScience, Inc. (NASDAQ:OVAS), VIVUS Inc. (NASDAQ:VVUS), Stratasys Ltd. (NASDAQ:SSYS)
World Wrestling Entertainment Inc. (NYSE:WWE), with shares declined -14.71%, closed at $14.09.
OvaScience, Inc. (NASDAQ:OVAS), with shares dropped -12.17%, settled at $38.18.
VIVUS Inc. (NASDAQ:VVUS), with shares dipped -1.95%, and closed at $2.52.
Stratasys Ltd. (NASDAQ:SSYS), plummeted -1.94%, and closed at $53.66.
Latest NEWS regarding these Stocks are depicted underneath:
World Wrestling Entertainment Inc. (NYSE:WWE)
World Wrestling Entertainment Inc. (WWE), in partnership with Seth Green’s Stoopid Buddy Stoodios, will debut a new, animated short-form comedy series entitled Camp WWE. Imagine WWE Superstars and Divas when they were kids at their favorite summer camp…which happens to be run by none other than Mr. McMahon – add in shock-value, slapstick humor and social satire – and you have WWE’s first adult comedy, which will debut later this year.
“We’re insanely excited about this collaboration,” said Green. “WWE is one of the most heartfelt and professional organizations I’ve worked with. We’re beyond happy to assist them realize this vision.”
World Wrestling Entertainment, Inc., an integrated media and entertainment corporation, engages in the sports entertainment business in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
OvaScience, Inc. (NASDAQ:OVAS)
On Saturday, OvaScience, Inc. (OVAS), declared that additional clinical experience of the Corporation’s AUGMENTSM treatment demonstrated improved pregnancy rates in women who had failed three to seven preceding in vitro fertilization (IVF) cycles. These results were stated at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting being held in San Francisco, CA. The AUGMENT treatment is not accessible in the United States.
The AUGMENT treatment is a fertility treatment specifically designed to use the mitochondria, or energy, from a woman’s own egg precursor cells – immature egg cells found inside the protective ovarian lining – to improve egg health. The treatment is accessible to patients in select international IVF clinics.
“The positive clinical evidence continues to build in support of our AUGMENT treatment,” stated Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “These improved pregnancy rates in women who have failed IVF multiple times, coupled with similar encouraging clinical AUGMENT experiences at other IVF clinics, provide physicians and patients with important information about how the AUGMENT treatment may improve egg health in women with infertility.”
OvaScience, Inc., a life science corporation, engages in the discovery, development, and commercialization of new treatments for infertility. The corporation’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries.
VIVUS Inc. (NASDAQ:VVUS)
VIVUS Inc. (VVUS), declared an operational update, counting certain key corporate decisions and plans regarding Qsymia® (phentermine and topiramate extended-release) capsules CIV. These plans comprise further investments in high-value, consumer-focused digital media projects in support of obesity education and Qsymia, and focusing the Qsymia field sales organization of about 100 territories on the most productive target areas. Administration will continue discussions with US and EU regulatory authorities regarding Qsymia development and potential cost-saving measures related to the planned cardiovascular outcomes trial (CVOT), and will aim to further improve corporate efficiency and control costs while maintaining and extending the value of avanafil.
VIVUS plans to talk about with U.S. regulatory authorities and key consultants potential cost-saving alternatives with respect to the Qsymia CVOT, known as AQCLAIM. The Corporation is also in the process of pursuing approval for Qsymia in the EU and other key countries, in addition to new indications in other chronic diseases such as obstructive sleep apnea (OSA) and type 2 diabetes. VIVUS plans to optimize spending while pursuing these potential objectives.
VIVUS, Inc., a biopharmaceutical corporation, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union.
Stratasys Ltd. (NASDAQ:SSYS)
On Friday afternoon, Stratasys Ltd. (SSYS), teamed up with the Science Museum of Minnesota for its exhibition: “Space: An Out-of-Gravity Experience.”
The Science Museum of Minnesota, in partnership with the California Science Center, NASA and other science museums, developed the exhibition to educate people about the challenges of living and working in space. The exhibit showcases a Stratasys 3D Printer to demonstrate how space explorers would be able to conveniently 3D print spare parts and tools.
The exhibit will feature Stratasys’ uPrint SE Plus 3D Printer and it will be on display over the next three years, making stops in California, Oregon, Pennsylvania and Massachusetts through June 2018.
Stratasys Ltd. provides additive manufacturing (AM) solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts. Its AM systems utilize its patented fused deposition modeling and inkjet-based PolyJet technologies to enable the production of prototypes, tools used for production and manufactured goods directly from three-dimensional (3D) CAD files or other 3D content.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
